openPR Logo
Press release

Oral Biologics Market Aims to Expand at Double-Digit Growth Rate

11-14-2019 06:40 AM CET | Health & Medicine

Press release from: Coherent Market Insights

Oral Biologics

Oral Biologics

In February 2019, researchers at Massachusetts Institute of Technology (MIT) developed a drug capsule with the potential to deliver an oral insulin named SOMA capsule, thereby replacing (or eliminating) the need to administer insulin via injections multiple times a day for patients with type 1 diabetes. The researchers stated that the drugs is currently under preclinical studies and is expected to enter clinical trials by 2022.

The research was funded by Novo Nordisk, the National Institutes of Health, a National Science Foundation Graduate Research Fellowship, Brigham and Women’s Hospital, a Viking Olaf Bjork Research Scholarship, and the MIT Undergraduate Research Opportunities Program.

Get Free Request a sample report @ https://www.coherentmarketinsights.com/insight/request-sample/989

Increasing number of strategic moves such as collaborations and innovations by key players is an important factor driving global oral biologics market growth in near future.

For instance, in 2016, Rani Therapeutics announced collaboration with Medimmune, a research and development subsidiary of AstraZeneca, to evaluate Rani Therapeutics’ novel oral drug delivering platform. This collaboration is expected to facilitate feasibility studies of drugs and test biologic molecules in the area of metabolic disease, to evaluate oral delivery of molecules. The objective of this collaboration is to deliver biologics orally, in order to increase compliance and improve patients’ lives globally.

The U.S. is expected to be most lucrative market for oral biologics in North America, as it is the biggest pharmaceutical market with high presence of major players. Furthermore, high healthcare expenditure, healthcare awareness, and high adoption rate of novel drugs make the U.S. most prominent market for oral biologics.

Key players in the market are focusing on gaining the U.S. FDA approval for their oral biologics and launch them in the market. For instance, in March 2019, Novo Nordisk A/S submitted two New Drug Applications (NDAs) to the U.S. Food and Drug Administration (FDA) for oral semaglutide, the once-daily glucagon-like peptide-1 (GLP-1) receptor agonist in a pill.

Get Free PDF Brochure of Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/989

Approval and launch of novel oral biologics in the U.S. is expected to significantly drive the North America oral biologics market growth over the forecast period.

According to Labiotech.eu, 2018, around half of the top 100 drug sales will be biologics by 2022. Moreover, an estimated 2,700 biologics are currently in development, which means they can create a conducive biologics market post approval. However, the biological drugs are administered parentally, which can result in high treatment costs and lower adherence rates.

According to the research conducted by Rani Therapeutics in 2018, around 62% patients and 86% physicians reported that patients either skip their injection or consistently fail to inject the drug as prescribed. The research further stated that around 70% rheumatologists and 92% gastroenterologists believe that availability of pills would significantly increase patient compliance rates.

Thus, the availability of biologics in the form of oral pills is expected to increase compliance rate and patient comfort, which can significantly improve the patients’ health by changing the course of the disease and preventing further complications. Moreover, oral biologics could also lower medication costs and improve access while improving the health of millions with chronic diseases globally.

The U.S. Food and Drug Administration (FDA) issues guidelines and regulates biologics including: vaccines, blood and blood products, cellular and gene therapy products tissue and tissue products, and allergenics.

The Center for Biologics Evaluation and Research (CBER) is a part of FDA that regulates biological products for human use, under applicable federal laws, including the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act.

CBER ensures that biological products are safe and effective and are readily available. CBER also promotes the safe and appropriate use of biological products.

CBER encourages manufacturers to use appropriate standards in the development of medical products. The use of appropriate standards can facilitate product development and provide a more efficient evaluation of regulatory submissions, including investigational new drug applications (INDs), biologics license applications (BLAs), new drug applications (NDAs), investigational device exemptions (IDEs), premarket approval applications, and premarket notifications, supplements, and amendments.

Inquire about Discount on this Report @ https://www.coherentmarketinsights.com/insight/request-discount/989

Key players operating in the global oral biologics market include Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals, Inc., Rani Therapeutics, Entera Bio Ltd., Allergan plc, Emisphere Technologies, Inc., Enteris BioPharma, Inc., Chiasma, Inc., and Allena Pharmaceuticals, Inc.

Contact Us:
Mr. Raj Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
Visit our Blog: https://hospitalhealthcareblog.wordpress.com/

About Us:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Oral Biologics Market Aims to Expand at Double-Digit Growth Rate here

News-ID: 1867010 • Views: 270

More Releases from Coherent Market Insights

Ransomware Protection Market Projected to Reach Massive Hike till 2026
The subject matter experts and team of highly-skilled researchers have put in hours of work to collate an authentic research report on the global Ransomware Protection Market. Analysts have studied the various products in the market and offered an unbiased opinion about the factors that likely to drive the market and restrain it. For a detailed study, researchers have used primary and secondary research methodologies. Analysts have also studied the
Network Security Firewall Market Growing With Symsoft, Anam Technologies, Cellus …
In the market research study namely, Global Network Security Firewall Market, 2018 has been considered as the base year and 2018 to 2026 the forecast period to estimate the market size for Keyword. The report gives a comprehensive discussion on the market current flow and patterns, industry development drivers, market share, sales volume, informative diagrams, supply and demand, and numerous different aspects. Featuring global and regional data and over top
Hydrogen Vehicle Market To Grow With Toyota Motor Corporation, Hyundai Motor Com …
The report covers Hydrogen Vehicle Market product demand and supply, revenue, profitability, outcomes, consumer trends, size, major segments and share along with company profiles of the key shareholders performing in the year 2018 to 2026. This report examines and evaluates the global as well as the regional scale of the Hydrogen Vehicle market. This report offers modern trends and opportunities which will help the industry player to grasp market growth.
Chloroform Market Market to Expand Substantially Owing to Technological Innovati …
This Report is a proficient study by Coherent Market Insights the report is an essential reference for those who are looks for detailes information for Chloroform Market. Chloroform Market Reseasch Report is a professional and in-depth study on the current state which focucses on the major drivers and restraints for the key players. Chloroform Industry Reserach Report provides granular analysis of the market Share, Segmentation, revenue forecasts and geographical regions of

All 5 Releases


More Releases for Bio

Global Bio Polyurethane (Bio-based Polyurethane) Market 2018 - BASF, Lubrizol
Apex Market Reports, recently published a detailed market research study focused on the “Bio Polyurethane (Bio-based Polyurethane) Market” across the global, regional and country level. The report provides 360° analysis of “Bio Polyurethane (Bio-based Polyurethane) Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend
Global Bioplastics (Bio-plastics,Bio plastics) Market 2018 - Braskem, BASF
Apex Market Reports, recently published a detailed market research study focused on the “Bioplastics (Bio-plastics,Bio plastics) Market” across the global, regional and country level. The report provides 360° analysis of “Bioplastics (Bio-plastics,Bio plastics) Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of Bioplastics
Bio Electronics and Bio Sensors Market Forecasts, 2017-2025
Description: The global bio electronic market is valued USD $15 billion in 2016 and is expected to grow at a CAGR of 11.6% during the forecast period 2017-2025. The market is driven by various factors such as rapid advancement in semiconductor technology, high demand in implantable medical devices, increasing prevalence of neural and cardiac diseases among others. The emerging healthcare technologies such as lab on chip, ambulatory surgical centres, and personalized devices are
Bio Simulation Technology Market
Global Bio Simulation Technology Industry Bio Simulation Technology Market is estimated at $1.01 billion in 2015 and is projected to reach $2.99 billion by 2022 growing at a CAGR of 16.6% from 2015 to 2022. Reduction in the cost of drug discovery and development and risk of failure of drug molecule are some of the factors driving the market growth. Furthermore, R&D investments in biotechnology and pharmaceutical industries, growth in the
Global Bio-Polyethylene Terephthalate (Bio-PET) Market Research Report 2021
Qyresearchreports include new market research report “Global Bio-Polyethylene Terephthalate (Bio-PET) Market Research Report 2021″ to its huge collection of research reports. This market intelligence report serves its readers with an executive-level blueprint of the global Bio-Polyethylene Terephthalate (Bio-PET) market. Data from a number of paid and unpaid sources including press releases, journals, presentations, and white papers has been taken into account for collating this report. The various factors influencing the growth of
SHANE RADBONE CORPORATE BIO
Young, dynamic and highly successful Shane founded his own business, Executive Fitness Management at age 20 in 1991. After a successful career in football that took him as high as playing for Essendon, Shane appreciated the need to have more than just sport in his portfolio. However taking his on field attitude to the corporate arena, Executive Fitness Management (EFM) grew into Australia’s largest Corporate Fitness Company. It started with